Develops small-molecule precision cancer therapies designed to correct mutant tumor-suppressor proteins, including rezatapopt for patients with cancers linked to a specific mutation.
10-K for FY2025, filed Mar 6, 2026We are a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53…View ↗
Our lead product candidate, rezatapopt, is an orally available small molecule designed to potently and selectively correct p53 misfolding…View ↗
We are leveraging our precision oncology platform to develop a pipeline of orally available, potent and highly selective small molecule…View ↗
If approved, the company plans to sell its products through a focused sales and marketing organization to oncologists, who treat the patient populations for which its candidates are being developed.
10-K for FY2025, filed Mar 6, 2026
10-Q for Q3 FY2026, filed Nov 10, 2026
−$34.4MView ↗
8-K, filed Sep 2, 2026
All of the securities being sold in the offering are being sold by PMV Pharma. The gross proceeds from the offering, before deducting…View ↗
8-K, filed Aug 31, 2026
Overall response rate (ORR) of 46% (35/76 patients, including four confirmed complete responses, 29 confirmed partial responses, and two…View ↗
Broader platform focus
The older report described applying its platform to hotspot mutations in the tumor-suppressor protein and inhibitors of its normal form; the latest describes candidates targeting mutant forms of the protein or related cancers.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Mar 6, 2026We are a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53…View ↗
We believe the mechanism of action employed by PC14586 to structurally correct a specific p53 mutant and restore wild-type p53 activity…View ↗
In addition to targeting p53 hotspot mutants, we believe that our expertise and platform can also be applied to target other p53-related…View ↗
Competes with Jacobio Pharmaceuticals, Changchun GeneScience, Frontier Medicines, and Nutshell Therapeutics
10-K for FY2025, filed Mar 6, 2026We are a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53 mutations and other…View ↗
Loading...